louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00330577: 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients
Official title: 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Primary Open Angle Glaucoma
Ocular Hypertension
Lead sponsor: Aristotle University Of Thessaloniki
Sponsor class: OTHER
First posted: 2006-05-29
Enrollment: 30
Sex: ALL
Minimum age (years): 29
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the short-term mean 24-hour intraocular pressure control, 24-hour blood pressure effect and safety of Latanoprost/Timolol fixed combination given once in the evening with placebo once in the morning versus timolol maleate 0.5% given twice daily in patients with ocular hypertension and primary open-angle glaucoma.


Eligibility criteria: Inclusion Criteria:

* POAG
* OHT

Exclusion Criteria:

* Advanced glaucoma
* Arterial Hypertension

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Thessaloniki
country: Greece
facility: Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital
Study officials:
affiliation: Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital
name: AGP Konstas, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03314077: Quality Control and Evaluation in Standard COPD Management
Official title: Quality Control and Evaluation in Standard COPD Management
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COPD
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
Collaborators: name: Affiliated hospital of Guilin medical university,China
name: University hospital of Hubei university for nationalities,China
name: TongjiChibi hospital,China
name: Central health center in Yongjiahe Town,China
name: Chinses PLA general hospital
name: the second Xiangya hospital of Central sounth university
name: the fourth affiliated hospital, Zhejiang university school of medcine
name: First Hospital of China Medical University
name: Peking University Third Hospital
name: Huashan Hospital
name: First Affiliated Hospital Xi'an Jiaotong University
name: Shanghai Zhongshan Hospital
name: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
name: Yiwu Central Hospital
name: Shanghai Xuhui Central Hospital
name: Sijing hospital of Songjiang District in Shanghai
name: Youxian People's Hospital
name: Tong Ren hospital Shanghai Jiao Tong university school of medicine
name: Zhejiang Putuo Hospital
name: Jing-An District Center Hospital of Shanghai (Huashan Hospital Fudan University Jing-An Branch), Shanghai Medical College, Fudan University
First posted: 2017-10-19
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Clinic-based population

Brief summary: There is lack of quality control and evaluation indexes for standard COPD management in hospitals in China, leading to nonstandard in COPD management and discrepancy in therapeutic efficiency. This study focuses on establishing quality control and evaluation indexes for standard COPD management in hospitals in China, and evaluating the therapeutic efficiency after standard COPD management. This part is a prospective cohort which lasts 2 years. After standard COPD management according to GOLD 2017 by doctors in hospitals in China, patients will be followed up for their outcome after 1 year. Several indexes will be selected to evaluate the quality control of standard COPD management and its efficiency. The controls are from hospital-based subjects with a retrospective cohort study.


Eligibility criteria: Inclusion Criteria:

* 1.Clinical manifestation of COPD; post bronchodilator FEV1/FVC\<0.70

Exclusion Criteria:

* 1. lung cancer. 2. Any history of psychiatric disorders. 3.HIV positive. 4.Breastfeeding, pregnancy or planning to be pregnant. 5.Estimated lifetime less than 1 years due to underlying diseases.

Primary outcomes:
measure: Change in spirometry
timeFrame: 1 years
Secondary outcomes:
measure: Morbidity of acute exacerbation in 1 years
timeFrame: 1 year
Other outcomes:
Locations:
city: Chibi
country: China
facility: TongjiChibi hospital
state: Hubei
city: Wuhan
country: China
facility: Tongji hospital
state: Hubei
Study officials:
References:
Clinical trial NCT02757677: Evaluation of Blood Flow Characteristics in Glaucoma Using Optical Coherence Tomography Angiography (OCT-A).
Official title: A Cross-sectional, Prospective, Observational Study to Evaluate Blood Flow Characteristics in Glaucoma Patients Using Optical Coherence Tomography Based Angiography (OCT-A).
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Glaucoma
Lead sponsor: Swiss Vision Network
Sponsor class: OTHER
First posted: 2016-05-02
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients will be enrolled from glaucoma clinics of the Montchoisi glaucoma center.

Brief summary: The investigators aim to evaluate the efficacy of the new Optical Coherence Tomography based Angiography (OCT-A) softwares in the diagnosis and management of glaucoma.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of open angle glaucoma (OAG) including pseudo-exfoliative and pigmentary glaucoma.
* Documented glaucomatous visual field damage (in the previous 12 months with mean defect (MD) \> 2.0 dB)
* Structural and/or functional glaucomatous damage
* Have given written informed consent, prior to any investigational procedures

Exclusion Criteria:

* Patients with allergy to corneal anesthetic
* Patients not able to understand the character and individual consequences of the investigation
* Participation in other clinical research within the last 4 weeks
* Other diseases that may cause visual field loss or optic disc abnormalities
* Refractive error of \> +3.00D or \< -7.00D

Primary outcomes:
measure: Macular and optic nerve head bloodflow, as measured by OCT-A macular and optic nerve head vessel density (%)
timeFrame: Up to 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: Glaucoma center, Montchoisi clinic
Study officials:
affiliation: Glaucoma center, Montchoisi clinic, Swiss vision network
name: Kaweh Mansouri, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02059577: Nutritional and Dietary Treatment Study for Children/Adults With Autism
Official title: Nutritional and Dietary Treatment Study for Children/Adults With Autism
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Autism
Keywords: vitamins
minerals
essential fatty acids
Epsom salts
carnitine
digestive enzymes
gluten-free casein-free diet
Lead sponsor: Arizona State University
Sponsor class: OTHER
Collaborators: name: Autism Research Instittute
First posted: 2014-02-11
Enrollment: 120
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 70 children and adults with autism spectrum disorders will be enrolled in a 1-year, single-blind treatment study. Assessments will be conducted at the beginning and end of the study, including measurements of nutritional, metabolic, and digestive status and assessments of autism severity and overall functioning. Half of the participants will be randomized into a treatment study, and half will be randomized to no changes in their current treatments. Treatments will be added in a sequential manner over 12 months, including vitamin/minerals, essential fatty acids, carnitine, digestive enzymes, and healthy, gluten-free, casein-free diets. A dedicated team of nutritionists, nurses, and physicians will support and monitor the participants throughout the study.

A group of 50 neurotypical children and adults, of similar age and gender, will be included for comparison.


Eligibility criteria: Inclusion Criteria:

Inclusion Criteria - Autism Group

1. Diagnosis of autism spectrum disorder (autism, PDD-NOS, or Asperger's) by a psychiatrist, psychologist, or developmental pediatrician
2. Verification of diagnosis by an ADOS evaluation (conducted by ASU staff)
3. Age of 2.5 years to 60 years

Enrollment Criteria - Non-autism Group

1. No diagnosed mental disorders, including autism spectrum disorders, ADHD, depression, anxiety, etc.
2. No first-degree relatives of individuals with autism (no siblings or parents)
3. Age of 2.5 years to 60 years -

Exclusion Criteria:

Exclusion Criteria - Autism Group

1. Major changes in behavioral or medical treatments in the previous two months, or intention to make such changes during the 12 months of the study.
2. Usage of nutritional supplements (vitamins, minerals essential fatty acids, carnitine) or special diets in the previous two months

Exclusion Criteria - Non-autism Group 1) Usage of nutritional supplements (vitamins, minerals essential fatty acids, carnitine) or special diets in the previous two months

-

Primary outcomes:
measure: Childhood Autism Rating Scale
timeFrame: 12 months
measure: Reynolds Intellectual Assessment Scales
timeFrame: 12 months
measure: Vineland Adaptive Behavior Scale
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tempe
country: United States
facility: Arizona State University
state: Arizona
Study officials:
affiliation: Arizona State University
name: James B. Adams, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06263777: Early Detection of Children With Developmental Disabilities in Assiut Governorate
Official title: Nurses Training Program for Early Detection of Children With Developmental Disabilities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Developmental Disability
Development Delay
Motor Delay
Down Syndrome
Autism Spectrum Disorder
Keywords: Nurses training
early detection
early intervention
developmental disabilities
children
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2024-02-16
Enrollment: 21
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The study aimed to determine the effectiveness of a designed training program for nurses toward early detection of developmental disabilities among children (0-3 years).

Detailed description: A group of twenty-one licensed nurses with professional experience ranging from 5 to 11 years participated in the study. The participants completed the measurements to evaluate their current knowledge, practice, and perception pre-, post-, and follow-up of the training program in relation to the early detection of disabilities.

Eligibility criteria: Inclusion Criteria:

* The study was conducted in selected health units in Assiut, an Upper Egypt Governorate, in selected villages:

  * far from the main government services,
  * without access to public or subsidized transportation to and from the selected villages, and
  * without the presence of any allied health professionals (physical therapists, occupational therapists, speech and language therapists, psychologists), who do not offer any of these medical services.

The selected nurses should be

* employed by the village health department in the public sector,
* locals of the village where the health unit is located,
* and untrained in the early identification or examination of disabled children.

Exclusion Criteria:

* other than inclusion criteria

Primary outcomes:
measure: Questionnaire of Screening and referral knowledge
timeFrame: 1 month
measure: Questionnaire of Disability Perception
timeFrame: 1 month
measure: questionnaire about Monitoring Practices
timeFrame: 1 month
measure: Follow up
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Banī Suwayf
country: Egypt
facility: Tayseer Saber Abdeldayem
state: Beni-Suef
Study officials:
affiliation: Beni-Suef University
name: Tayseer S Abdeldayem, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chödrön, G., Pizur-Barnekow, K., Viehweg, S., Puk-Ament, A., & Barger, B. (2019). Childcare providers' attitudes, knowledge, and practice related to developmental monitoring to promote early identification and referral Early Child Development and Care, 1-15. https://doi.org/10.1080/03004430.2019.1626373
Clinical trial NCT01235377: Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Official title: Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Keywords: prescribing patterns
thiazide
chlorthalidone
hydrochlorothiazide
target dose
cluster randomized trial
Lead sponsor: VA Pharmacy Benefits Management Strategic Healthcare Group
Sponsor class: FED
First posted: 2010-11-05
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This is a pilot study of a method to compare common, FDA-approved drugs in a clinic. Instead of putting single patients into one of two drug groups, the investigators will assign the doctors who prescribe these drugs for high blood pressure into two groups. One group of doctors has agreed to prescribe mostly ("favor") one drug, chlorthalidone, if that drug would be a good choice for a patient. The other group has agreed to prescribe mostly hydrochlorothiazide. For both groups, they will try to use the doses that were shown to be protective in other trials. If the doctors mostly prescribe the drug they agreed to favor, the investigators will be able to compare outcomes, like heart attacks, in the two groups.


Eligibility criteria: Inclusion Criteria:

* VA prescribers of thiazides for hypertension

Exclusion Criteria:

* at non-participating VA sites

Primary outcomes:
measure: Prescription Rates
timeFrame: nine months
Secondary outcomes:
measure: Factors Associated With Prescribing Patterns
timeFrame: nine months
Other outcomes:
Locations:
city: Hines
country: United States
facility: Edward Hines, Jr. VA Hospital
state: Illinois
city: Asheville
country: United States
facility: Charles George VAMC
state: North Carolina
city: Wilkes-Barre
country: United States
facility: Wilkes-Barre VA Medical Center
state: Pennsylvania
city: Columbia
country: United States
facility: WJB Dorn VA Medical Center
state: South Carolina
city: Orangeburg
country: United States
facility: WJB Dorn VAMC/Columbia Orangeburg VA Outpatient Clinic
state: South Carolina
Study officials:
affiliation: VA Pharmacy Benefits Management
name: Madeline McCarren, PhD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05422677: An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
Official title: An Observational Study to Evaluate the Effectiveness and Safety of the Treatment of Tamsulosin in Korean Adult Males Diagnosed With Benign Prostatic Hyperplasia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: BPH
Benign Prostatic Hyperplasia
Keywords: Tamsulosin
BPH
Benign Prostatic Hyperplasia
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2022-06-16
Enrollment: 4698
Sex: MALE
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Benign Prostatic Hyperplasia

Brief summary: In this study, BPH patients visited the institutions during the study period and the effectiveness and safety of the treatment of Tamsulosin(Hanmi Tams® Capsule) in real-practice.

During the routine medical visit, according to the investigator's judgment, with diagnosis that the Tamsulosin prescription is appropriate, and after deciding to start treatment, patients with BPH who agreed to participate in the study were administered Tamsulosin.

As this study is a non-interventional observational study, all subjects received prescriptions according to the routine treatment procedure, and there were no visits or procedures required according to the observational study protocol.

Detailed description: This study is a multicenter, prospective, non-interventional, observational study of men administering Tamsulosin(Hanmi Tams® Capsule) to treat BPH.

Data will be collected from patients receiving routine treatment at hospitals in South Korea. Each subject visit the institution according to the protocol that designed the follow-up visits for six months to examine the effectiveness and safety of Tamsulosin.

This study will approved by the institutions' IRBs and is in compliance with clinical research ethics regulations.

Eligibility criteria: Inclusion Criteria:

* Male was diagnosed with Benign Prostatic Hyperplasia
* Those who first started taking Hanmi Tams®
* Those who voluntarily consented in writing to this study

Exclusion Criteria:

* Patients for whom use of Hanmi Tams® is prohibited

Primary outcomes:
measure: LUTS (Lower Tract Symptoms) improvement effect evaluated in patients with BPH symptoms after Tamsulosin treatment
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Hanmi Pharmaceutical Company Limited
Study officials:
affiliation: Hanmi Pharmaceutical Company Limited
name: Ji-yeon Hong
role: STUDY_DIRECTOR
References:
Clinical trial NCT04265677: FamilyLink Family-Centered Rounds
Official title: FamilyLink Family-Centered Rounds Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Family Centered Rounds
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2020-02-11
Enrollment: 110
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study will be a pilot test of using FamilyLink software to bring parents of patients in the neonatal intensive care unit (NICU) virtually to the bedside during Family Centered Rounds.


Eligibility criteria: Inclusion Criteria:

* Patients admitted to the Blue Team in the NICU aged 0-365 days
* Parents/guardians of patients admitted to the Blue Team in the NICU aged ≥ 18 years
* Medical team members (physicians, nurse practitioners, fellows, residents, medical students, nurses) of patients admitted to the Blue Team in the NICU aged ≥ 18 years

Exclusion Criteria:

* Patients who are not discharged home from the NICU (e.g., transferred to another inpatient unit or another hospital)
* Parents/guardians of patients admitted to the Blue Team in the NICU who do not speak English, as a translator will not reliability be available to participate in rounds when the parent/guardian is not physically present
* Patients who have more than one admission to the Blue Team during our study period will only be included on their first admission

Primary outcomes:
measure: CAHPS Communication with Parent Subscale
timeFrame: Through study completion, approximately 3 months
Secondary outcomes:
measure: Rates of adverse events
timeFrame: Up to 6 months
measure: Hospital Length of Stay
timeFrame: Through study completion, approximately 3 months
measure: Breastmilk at discharge
timeFrame: Through study completion, approximately 3 months
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California-Davis
state: California
Study officials:
References:
Clinical trial NCT06466577: Clinical Study of CT 5400 RT for System Validation
Official title: Clinical Study of CT 5400 RT for System Validation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Performance and Safety
Lead sponsor: Philips Clinical & Medical Affairs Global
Sponsor class: INDUSTRY
Collaborators: name: Philips Healthcare (Suzhou) Co., Ltd.
First posted: 2024-06-20
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this clinical trial is to evaluate the efficacy and safety of the CT 5400 RT System.


Eligibility criteria: Inclusion Criteria:

* 18≤ Age ≤ 75 years old;
* Subjects with Clear consciousness; Subjects can cooperate and act autonomously;
* Subjects agree to participate in this clinical study and sign the subject's informed consent;
* Women subjects of childbearing age should have a negative pregnancy test and should have no plans to become pregnant in the next 6 months.

Exclusion Criteria:

* Subjects who do not have full capacity for civil conduct;
* Women subjects who are pregnant or in lactating phase;
* Subjects who have had a CT scan within one year;
* Subjects with a history of allergies or asthma, severe hepatic and renal insufficiency or hyperthyroidism in which are considered as contraindication for CT contrast-enhanced examination;
* According to the opinion of the investigator: any situation that may affect the evaluation of the results or expose subjects into health risk;
* Subjects with mental disorders who cannot cooperate with the examination

Primary outcomes:
measure: Clinical image quality
timeFrame: 14 days (anticipated)
Secondary outcomes:
measure: General function assessment
timeFrame: 14 days (anticipated)
measure: Convenience assessment
timeFrame: 14 days (anticipated)
measure: Workflow and stability assessment
timeFrame: 14 days (anticipated)
measure: Incidence of CT Scan-Emergent Adverse Events
timeFrame: 30 days (anticipated)
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Public Health Clinical Center
state: Shanghai
Study officials:
References: